Homburger on Tolremo Therapeutics’ Series A financing round
Homburger advised Tolremo therapeutics on the extension of its Series A financing round, bringing the total amount raised to USD 39 million (CHF 34.1 million). BioMedPartners led the round with participation from a new investor, Pierre Fabre Invest, as well as existing investors.
Tolremo’s mission is to stop non-genetic cancer drug resistance as it emerges by dismantling cancer’s earliest defenses to targeted therapies, thus surmounting a universal challenge for current and future targeted treatments.
The Homburger team was led by Dieter Gericke and Margrit Marti and comprised Francesco Bernasconi, Stefan Luginbühl, Thierry Burckhardt and Claudine Schär (all Corporate / M&A; Healthcare / Life Sciences) as well as Stefan Oesterhelt (Tax).
